Allovir Inc reports results for the quarter ended in September - Earnings Summary

Kalaris Therapeutics

08/11/2021 14:32

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss of 72
cents​​ per share for the quarter ended in September. The mean
expectation of four analysts for the quarter was for a loss
of 55 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Allovir Inc's reported EPS for the quarter was a loss of 72
cents​.
* The mean earnings estimate of analysts had risen by about 1.8%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Allovir Inc shares had fallen by 2.1% this quarter and
lost 36.2% so far this year.
* The company reported a quarterly loss of $45.51 million.
* Wall Street's median 12-month price target for Allovir Inc is
$44.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 8 at 02:32 p.m.
 ​All figures in US dollars unless otherwise stated